Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

ABVC BioPharma Selects Additional Vitargus Phase II Study Site

By: NewMediaWire

September 09, 2022 at 08:30 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

New Australia Site Confirmed to Participate in the Study

Fremont, CA - (NewMediaWire) - September 09, 2022 - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced a new clinical site in Australia has been selected to participate in the Phase II clinical study of Vitargus®, the first bio-degradable vitreous substitute to facilitate retina re-attachment surgery. The new site, located at the Sydney Eye Hospital in Sydney, New South Wales, will join East Melbourne Eye Group in East Melbourne, Victoria, Australia and Ramathibodi Hospital and Srinagarind Hospital in Thailand, to participate in the study.

The Sydney Eye Hospital is a well-established site for clinical trials with over 10 years’ experience including 23 completed and 22 on-going ophthalmology studies. The site has sufficient staff and resources to conduct the trial to a high standard with a potential enrollment rate of 10 subjects per week.

“We are pleased to confirm that the Sydney Eye Hospital will join our Phase II clinical study. As a well-established ophthalmology clinical study site, the Sydney Eye Hospital will conduct the study at the highest quality standard and, as a result, increase the overall patient recruiting rate,” said Dr. Howard Doong, Chief Executive Officer of the Company. Dr. Doong further noted, “According to iHealthcareAnalyst, Inc., the global market for retinal surgery devices is expected to reach $3.7 billion by 2027 driven by a rising geriatric population worldwide.”

About ABVC BioPharma

ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process at world-famous research institutions (such as Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center). For Vitargus®, the company intends to conduct the clinical trials through Phase III at various locations throughout the globe.

Forward-Looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Contact:

ICR, LLC

Stephanie Oshchepkov

Phone: +1 (203) 682-7175

Email: Stephanie.Oshchepkov@icrinc.com

View the original release on www.newmediawire.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	243.11	+5.61 (2.36%)
AAPL	297.62	+1.67 (0.56%)
AMD	531.51	+19.03 (3.71%)
BAC	56.26	-0.27 (-0.49%)
GOOG	366.71	+4.61 (1.27%)
META	576.14	+8.56 (1.51%)
MSFT	377.96	-0.95 (-0.25%)
NVDA	209.73	+5.08 (2.48%)
ORCL	185.08	+1.55 (0.84%)
TSLA	394.96	-1.42 (-0.36%)